Phase II Clinical trial of personalized peptide vaccine for patients with various types of cancers - Effect of sequencial change of vaccine antigens
Phase 2
- Conditions
- malignant tumor
- Registration Number
- JPRN-UMIN000010068
- Lead Sponsor
- Kurume University Cancer Vaccine Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
The following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2) Patients with the past history of severe allergic reactions. 3) Pregnant, nursing, or who wants pregnancy. Patients with no acceptance of use of effective contraception during and for at least 70 days after study participation. 4) Patients with the past history of cancer peptide vaccinations. 5) Patients with the past history of cancer peptide vaccinations.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of antigen-specific immune responses after 12 and 18 times of vaccinations.
- Secondary Outcome Measures
Name Time Method 1. Adverse effects and safety of personalized peptide vaccination are evaluated based on the CTCAE Version 4.0 2. Overall survival